Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avid Bioservices, Inc.

https://avidbio.com/

Latest From Avid Bioservices, Inc.

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

Strategy Sales & Earnings

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

Commercial Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

M & A Business Strategies

Roche Disappointed By English Funding Rejection For Gavreto But Will Not Appeal

Health technology assessment institute NICE said that uncertainty in the clinical evidence for Gavreto means that cost-effectiveness estimates are also uncertain for the drug, which is approved for treating RET fusion-positive advanced non-small cell lung cancer and is reimbursed in 10 European countries.

United Kingdom Cost Effectiveness
See All

Company Information

  • Industry
  • Contract Manufacturing Organization
  • Other Names / Subsidiaries
    • Techniclone Corporation Peregrine Pharmaceuticals, Inc.
UsernamePublicRestriction

Register